Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dent

Showing results (21-30 of 395) with videos related to

Pageof 40
Sort By:
Molecular Cancer Therapeutics|July 15, 2004
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?Steven Grant, Paul Dent
Current Drug Targets|June 23, 2007
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemiasSteven Grant, Paul Dent
Cancer Biology & Therapy|January 11, 2005
Irofulven: resurgence for alkylating therapy in cancer?Paul Dent, Steven Grant
Cancer Biology & Therapy|April 27, 2004
Activation of MAP kinase pathways by TRAIL: don't expect the obviousSteven Grant, Paul Dent
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Kinase inhibitors and cytotoxic drug resistanceSteven Grant, Paul Dent
Expert Opinion on Therapeutic Targets|November 12, 2019
Not the comfy chair! Cancer drugs that act against multiple active sitesLaurence Booth, Andrew Poklepovic, Paul Dent
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514AYun Dai, Paul Dent, Steven Grant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinomaMichael Hagan, Adly Yacoub, Paul Dent
Immunometabolism|December 31, 2019
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory ImmunotherapiesPaul Dent, Laurence Booth, Andrew Poklepovic
Molecular Pharmacology|December 4, 2003
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xLYun Dai, Paul Dent, Steven Grant
Pageof 40

Showing results (21-30 of 395) with videos related to

Sort By:
Pageof 40
Molecular Cancer Therapeutics|July 15, 2004
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?Steven Grant, Paul Dent
Current Drug Targets|June 23, 2007
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemiasSteven Grant, Paul Dent
Cancer Biology & Therapy|January 11, 2005
Irofulven: resurgence for alkylating therapy in cancer?Paul Dent, Steven Grant
Cancer Biology & Therapy|April 27, 2004
Activation of MAP kinase pathways by TRAIL: don't expect the obviousSteven Grant, Paul Dent
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Kinase inhibitors and cytotoxic drug resistanceSteven Grant, Paul Dent
Expert Opinion on Therapeutic Targets|November 12, 2019
Not the comfy chair! Cancer drugs that act against multiple active sitesLaurence Booth, Andrew Poklepovic, Paul Dent
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514AYun Dai, Paul Dent, Steven Grant
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinomaMichael Hagan, Adly Yacoub, Paul Dent
Immunometabolism|December 31, 2019
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory ImmunotherapiesPaul Dent, Laurence Booth, Andrew Poklepovic
Molecular Pharmacology|December 4, 2003
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xLYun Dai, Paul Dent, Steven Grant
Pageof 40